TY - JOUR
T1 - Hepatokine α1-Microglobulin Signaling Exacerbates Inflammation and Disturbs Fibrotic Repair in Mouse Myocardial Infarction
AU - Hakuno, Daihiko
AU - Kimura, Masahiro
AU - Ito, Shinji
AU - Satoh, Junko
AU - Nakashima, Yasuhiro
AU - Horie, Takahiro
AU - Kuwabara, Yasuhide
AU - Nishiga, Masataka
AU - Ide, Yuya
AU - Baba, Osamu
AU - Nishi, Hitoo
AU - Nakao, Tetsushi
AU - Nishino, Tomohiro
AU - Nakazeki, Fumiko
AU - Koyama, Satoshi
AU - Hanada, Ritsuko
AU - Randolph, Ruiz R.
AU - Endo, Jin
AU - Kimura, Takeshi
AU - Ono, Koh
N1 - Funding Information:
We thank Naoya Sowa for providing technical assistance and members of the Institute for Advancement of Clinical and Translational Science (iACT), Kyoto University Hospital for helpful discussion. This work was supported by grants from the Translational Research Acceleration Network Program of the iACT and the Japan Agency for Medical Research and Development (Grant Number A41) and grants from Suzuken Memorial Foundation to D.H.
Publisher Copyright:
© 2018, The Author(s).
PY - 2018/12/1
Y1 - 2018/12/1
N2 - Acute cardiac rupture and adverse left ventricular (LV) remodeling causing heart failure are serious complications of acute myocardial infarction (MI). While cardio-hepatic interactions have been recognized, their role in MI remains unknown. We treated cultured cardiomyocytes with conditioned media from various cell types and analyzed the media by mass spectrometry to identify α1-microglobulin (AM) as an Akt-activating hepatokine. In mouse MI model, AM protein transiently distributed in the infarct and border zones during the acute phase, reflecting infiltration of AM-bound macrophages. AM stimulation activated Akt, NFκB, and ERK signaling and enhanced inflammation as well as macrophage migration and polarization, while inhibited fibrogenesis-related mRNA expression in cultured macrophages and cardiac fibroblasts. Intramyocardial AM administration exacerbated macrophage infiltration, inflammation, and matrix metalloproteinase 9 mRNA expression in the infarct and border zones, whereas disturbed fibrotic repair, then provoked acute cardiac rupture in MI. Shotgun proteomics and lipid pull-down analysis found that AM partly binds to phosphatidic acid (PA) for its signaling and function. Furthermore, systemic delivery of a selective inhibitor of diacylglycerol kinase α-mediated PA synthesis notably reduced macrophage infiltration, inflammation, matrix metalloproteinase activity, and adverse LV remodeling in MI. Therefore, targeting AM signaling could be a novel pharmacological option to mitigate adverse LV remodeling in MI.
AB - Acute cardiac rupture and adverse left ventricular (LV) remodeling causing heart failure are serious complications of acute myocardial infarction (MI). While cardio-hepatic interactions have been recognized, their role in MI remains unknown. We treated cultured cardiomyocytes with conditioned media from various cell types and analyzed the media by mass spectrometry to identify α1-microglobulin (AM) as an Akt-activating hepatokine. In mouse MI model, AM protein transiently distributed in the infarct and border zones during the acute phase, reflecting infiltration of AM-bound macrophages. AM stimulation activated Akt, NFκB, and ERK signaling and enhanced inflammation as well as macrophage migration and polarization, while inhibited fibrogenesis-related mRNA expression in cultured macrophages and cardiac fibroblasts. Intramyocardial AM administration exacerbated macrophage infiltration, inflammation, and matrix metalloproteinase 9 mRNA expression in the infarct and border zones, whereas disturbed fibrotic repair, then provoked acute cardiac rupture in MI. Shotgun proteomics and lipid pull-down analysis found that AM partly binds to phosphatidic acid (PA) for its signaling and function. Furthermore, systemic delivery of a selective inhibitor of diacylglycerol kinase α-mediated PA synthesis notably reduced macrophage infiltration, inflammation, matrix metalloproteinase activity, and adverse LV remodeling in MI. Therefore, targeting AM signaling could be a novel pharmacological option to mitigate adverse LV remodeling in MI.
UR - http://www.scopus.com/inward/record.url?scp=85056474728&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056474728&partnerID=8YFLogxK
U2 - 10.1038/s41598-018-35194-w
DO - 10.1038/s41598-018-35194-w
M3 - Article
C2 - 30425314
AN - SCOPUS:85056474728
SN - 2045-2322
VL - 8
JO - Scientific reports
JF - Scientific reports
IS - 1
M1 - 16749
ER -